Studies of DNA methylomes maintain monumental promise for biomedicine however are hampered by the technological challenges of analyzing many samples cost-effectively. Recently, a serious extension of the earlier Infinium HumanMethylation27 BeadChip® (Illumina, Inc. CA, USA), known as Infinium HumanMethylation450 (Infinium Methylation 450Ok; Illumina, Inc. CA, USA) was developed. This upgraded expertise is a hybrid of two totally different chemical assays, the Infinium I and Infinium II assays, permitting (for 12 samples in parallel) evaluation of the methylation standing of greater than 480,000 cytosines distributed over the complete genome.
We used Infinium Methylation 450Ok to profile: first, the well-characterized HCT116 wild-type and double-knockout cell traces after which, 16 breast tissue samples (together with eight regular and eight main tumor samples). Absolute methylation values (β-values) had been extracted with the GenomeStudio™ software program after which subjected to detailed evaluation. In this text, we consider Infinium Methylation 450Ok on cell traces and tissue samples, highlighting some of its benefits but in addition some of its limitations. In explicit, we examine the methylation values of the Infinium I and Infinium II assays.
While this expertise appeared extremely sturdy as beforehand proven, we seen a divergence between the β-values retrieved from the sort I and kind II Infinium assays. Specifically, the β-values obtained from Infinium II probes had been much less correct and reproducible than these obtained from Infinium I probes. This means that information from the sort I and kind II assays must be thought of individually in any downstream bioinformatic evaluation. To have the ability to cope with the Infinium I and Infinium II information collectively, we developed and examined a brand new correction method, which we known as ‘peak-based correction’. The concept was to rescale the Infinium II information on the foundation of the Infinium I information. While this system must be seen as an approximation methodology, it considerably improves the high quality of Infinium II information.
Infinium 450Ok is a strong method in phrases of reagent prices, time of labor, pattern throughput and protection. It holds nice promise for the higher understanding of the epigenetic part in well being and illness. Yet, on account of the nature of its design comprising two totally different chemical assays, evaluation of the complete set of information will not be as straightforward as initially anticipated. Correction methods, reminiscent of the peak-based method proposed right here, are a step in the direction of enough output information evaluation.
Astrocytes set up speedy cell-to-cell communication via the launch of chemical transmitters. The underlying mechanisms and purposeful significance of this launch are, nonetheless, not properly understood. Here we determine an astrocytic vesicular compartment that’s competent for glutamate exocytosis. Using postembedding immunogold labeling of the rat hippocampus, we present that vesicular glutamate transporters (VGLUT1/2) and the vesicular SNARE protein, cellubrevin, are each expressed in small vesicular organelles that resemble synaptic vesicles of glutamatergic terminals.
Physiological, morphological, and histochemical characterization of three courses of interneurons in rat neostriatum.
Interneurons in lateral half of neostriatum had been studied in remoted slices from juvenile rats (16-20 d postnatal) by whole-cell, current-clamp recording at 33-34 levels C, adopted by intracellular staining with biocytin and double immunocytochemical or histochemical staining for parvalbumin, ChAT, and NADPH diaphorase. Medium-sized spiny neurons (MS cells) had distal dendrites with many spines and had been doubtless projection cells, whereas interneurons had dendrites with fewer spines. The neostriatal interneurons might be additional divided into three courses by physiological, chemical, and morphological standards.
The top notch of interneurons (fast-spiking cells, FS cells) fired very short-duration motion potentials with short-duration afterhyperpolarizations at fixed spike frequency throughout depolarizing present pulses. FS cells had extra destructive resting potentials and decrease enter resistances than the different two courses. At depolarized potentials, FS cells fired repetitive spikes in response to synaptic excitation. FS cells had been immunoreactive for parvalbumin. As all parvalbumin-immunoreactive cells in the neostriatum had been additionally immunoreactive for GABA, FS cells had been thought of to be GABAergic.
FS cells had been additional divided into two morphological varieties: FS cells with native dendritic fields and FS cells with prolonged dendritic fields. The axons of each varieties of FS cells had their densest collateralization inside or close to their dendritic fields. The different two courses of interneuron, PLTS cells (persistent and low-threshold spike cells) and LA cells (long-lasting afterhyperpolarization cells), had been distinguished from FS cells by longer-duration motion potentials and bigger enter resistances, had much less destructive resting potentials, and had longer-lasting afterhyperpolarizations.
 (CMV) (pLenti-GIII-CMV)) CASC3 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV632719 |
ABM |
1.0 ug DNA |
EUR 1626 |
 (UbC) (pLenti-GIII-UbC)) CASC3 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV632723 |
ABM |
1.0 ug DNA |
EUR 1626 |
 (EF1a) (pLenti-GIII-EF1a)) CASC3 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV632724 |
ABM |
1.0 ug DNA |
EUR 1626 |
 (CMV) (pLenti-GIII-CMV)) CASC1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|
LV704679 |
ABM |
1.0 ug DNA |
EUR 540 |
 (UbC) (pLenti-GIII-UbC)) CASC1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|
LV704683 |
ABM |
1.0 ug DNA |
EUR 540 |
 (EF1a) (pLenti-GIII-EF1a)) CASC1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|
LV704684 |
ABM |
1.0 ug DNA |
EUR 540 |
 (CMV) (pLenti-GIII-CMV)) CASC4P1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|
LV720485 |
ABM |
1.0 ug DNA |
Ask for price |
 (UbC) (pLenti-GIII-UbC)) CASC4P1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|
LV720489 |
ABM |
1.0 ug DNA |
Ask for price |
 (EF1a) (pLenti-GIII-EF1a)) CASC4P1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|
LV720490 |
ABM |
1.0 ug DNA |
Ask for price |
 (CMV) (pLenti-GIII-CMV-C-term-HA)) CASC3 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|
LV632720 |
ABM |
1.0 ug DNA |
EUR 1626 |
 (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)) CASC3 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|
LV632721 |
ABM |
1.0 ug DNA |
EUR 1695.6 |
 (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)) CASC3 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|
LV632722 |
ABM |
1.0 ug DNA |
EUR 1695.6 |
 (CMV) (pLenti-GIII-CMV-C-term-HA)) CASC1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|
LV704680 |
ABM |
1.0 ug DNA |
EUR 540 |
 (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)) CASC1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|
LV704681 |
ABM |
1.0 ug DNA |
EUR 609.6 |
 (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)) CASC1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|
LV704682 |
ABM |
1.0 ug DNA |
EUR 609.6 |
 CASC15 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|
TL318562 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
 CASC10 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|
TL320065 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
 (CMV) (pLenti-GIII-CMV-C-term-HA)) CASC4P1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-C-term-HA) |
|
LV720486 |
ABM |
1.0 ug DNA |
Ask for price |
 (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)) CASC4P1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro) |
|
LV720487 |
ABM |
1.0 ug DNA |
Ask for price |
 (CMV) (pLenti-GIII-CMV-RFP-2A-Puro)) CASC4P1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV-RFP-2A-Puro) |
|
LV720488 |
ABM |
1.0 ug DNA |
Ask for price |
 Casc1 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|
TL705204 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
 Casc3 - Rat, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|
TL713161 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
 CASC2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|
TL318162 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
 CASC3 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|
TL314191 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
 Casc3 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|
TL506170 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
 Casc1 - Mouse, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|
TL508351 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
 CASC1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector |
|
TL305646 |
Origene Technologies GmbH |
5 µg/vial |
Ask for price |
 (pORF)) CASC4 ORF Vector (Human) (pORF) |
|
ORF001883 |
ABM |
1.0 ug DNA |
EUR 114 |
CASC4 ORF Vector (Human) (pORF) |
|
ORF001884 |
ABM |
1.0 ug DNA |
EUR 114 |
 (pORF)) Casc4 ORF Vector (Mouse) (pORF) |
|
ORF040409 |
ABM |
1.0 ug DNA |
EUR 607.2 |
Casc4 ORF Vector (Mouse) (pORF) |
|
ORF040410 |
ABM |
1.0 ug DNA |
EUR 607.2 |
Casc4 ORF Vector (Mouse) (pORF) |
|
ORF040411 |
ABM |
1.0 ug DNA |
EUR 607.2 |
Casc4 ORF Vector (Mouse) (pORF) |
|
ORF040412 |
ABM |
1.0 ug DNA |
EUR 607.2 |
Casc4 ORF Vector (Mouse) (pORF) |
|
ORF040413 |
ABM |
1.0 ug DNA |
EUR 607.2 |
 (pPM-C-HA)) CASC4 Protein Vector (Mouse) (pPM-C-HA) |
|
PV161636 |
ABM |
500 ng |
EUR 723.6 |
CASC4 Protein Vector (Mouse) (pPM-C-HA) |
|
PV161640 |
ABM |
500 ng |
EUR 723.6 |
CASC4 Protein Vector (Mouse) (pPM-C-HA) |
|
PV161644 |
ABM |
500 ng |
EUR 723.6 |
CASC4 Protein Vector (Mouse) (pPM-C-HA) |
|
PV161648 |
ABM |
500 ng |
EUR 723.6 |
CASC4 Protein Vector (Mouse) (pPM-C-HA) |
|
PV161652 |
ABM |
500 ng |
EUR 723.6 |
 (pPM-C-HA)) CASC4 Protein Vector (Human) (pPM-C-HA) |
|
PV007531 |
ABM |
500 ng |
EUR 394.8 |
CASC4 Protein Vector (Human) (pPM-C-HA) |
|
PV007535 |
ABM |
500 ng |
EUR 394.8 |
 Cas9 Nickase Lentiviral Vector |
|
K005 |
ABM |
10 ug |
EUR 135 |
|
Description: N/A |
 (pPB-C-His)) CASC4 Protein Vector (Mouse) (pPB-C-His) |
|
PV161634 |
ABM |
500 ng |
EUR 723.6 |
 (pPB-N-His)) CASC4 Protein Vector (Mouse) (pPB-N-His) |
|
PV161635 |
ABM |
500 ng |
EUR 723.6 |
 (pPM-C-His)) CASC4 Protein Vector (Mouse) (pPM-C-His) |
|
PV161637 |
ABM |
500 ng |
EUR 723.6 |
CASC4 Protein Vector (Mouse) (pPB-C-His) |
|
PV161638 |
ABM |
500 ng |
EUR 723.6 |
CASC4 Protein Vector (Mouse) (pPB-N-His) |
|
PV161639 |
ABM |
500 ng |
EUR 723.6 |
CASC4 Protein Vector (Mouse) (pPM-C-His) |
|
PV161641 |
ABM |
500 ng |
EUR 723.6 |
CASC4 Protein Vector (Mouse) (pPB-C-His) |
|
PV161642 |
ABM |
500 ng |
EUR 723.6 |
CASC4 Protein Vector (Mouse) (pPB-N-His) |
|
PV161643 |
ABM |
500 ng |
EUR 723.6 |
CASC4 Protein Vector (Mouse) (pPM-C-His) |
|
PV161645 |
ABM |
500 ng |
EUR 723.6 |
CASC4 Protein Vector (Mouse) (pPB-C-His) |
|
PV161646 |
ABM |
500 ng |
EUR 723.6 |
CASC4 Protein Vector (Mouse) (pPB-N-His) |
|
PV161647 |
ABM |
500 ng |
EUR 723.6 |
CASC4 Protein Vector (Mouse) (pPM-C-His) |
|
PV161649 |
ABM |
500 ng |
EUR 723.6 |
CASC4 Protein Vector (Mouse) (pPB-C-His) |
|
PV161650 |
ABM |
500 ng |
EUR 723.6 |
CASC4 Protein Vector (Mouse) (pPB-N-His) |
|
PV161651 |
ABM |
500 ng |
EUR 723.6 |
CASC4 Protein Vector (Mouse) (pPM-C-His) |
|
PV161653 |
ABM |
500 ng |
EUR 723.6 |
 (pPB-C-His)) CASC4 Protein Vector (Human) (pPB-C-His) |
|
PV007529 |
ABM |
500 ng |
EUR 394.8 |
 (pPB-N-His)) CASC4 Protein Vector (Human) (pPB-N-His) |
|
PV007530 |
ABM |
500 ng |
EUR 394.8 |
 (pPM-C-His)) CASC4 Protein Vector (Human) (pPM-C-His) |
|
PV007532 |
ABM |
500 ng |
EUR 394.8 |
CASC4 Protein Vector (Human) (pPB-C-His) |
|
PV007533 |
ABM |
500 ng |
EUR 394.8 |
CASC4 Protein Vector (Human) (pPB-N-His) |
|
PV007534 |
ABM |
500 ng |
EUR 394.8 |
CASC4 Protein Vector (Human) (pPM-C-His) |
|
PV007536 |
ABM |
500 ng |
EUR 394.8 |
 Cas9 Nuclease Lentiviral Vector |
|
K002 |
ABM |
10 ug |
EUR 135 |
|
Description: N/A |
, 0.5 ml each, >10^7 TU/ml.) Casc4 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|
TL508278V |
Origene Technologies GmbH |
500 ul each |
Ask for price |
, 0.5 ml each, >10^7 TU/ml.) CASC4 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml. |
|
TL305645V |
Origene Technologies GmbH |
500 ul each |
Ask for price |
 Cas9 Double Mutant Lentiviral Vector |
|
K012 |
ABM |
10 ug |
EUR 395 |
|
Description: N/A |
 CD Lentiviral Vector |
|
LV678 |
ABM |
10 μg |
EUR 950 |
 dCas9-KRAB Lentiviral Vector |
|
K203 |
ABM |
10 ug |
EUR 165 |
|
Description: N/A |
 dCas9-DNMT3A Lentiviral Vector |
|
K091 |
ABM |
10 µg, Titer: N/A |
EUR 395 |
|
Description: N/A |
 dCas9-TET1CD Lentiviral Vector |
|
K096 |
ABM |
10 µg, Titer: N/A |
EUR 395 |
|
Description: N/A |
 Green Kit. Baculovirus GFP vector. |
|
K20 |
AB Vector LLC |
1 Kit |
EUR 695 |
|
|
|
Description: Protein expression |
 ProGreen. Baculovirus GFP marker vector. |
|
A1 |
AB Vector LLC |
25 ul |
EUR 420 |
|
|
|
Description: Protein expression |
 Antibody) Protein CASC4 (CASC4) Antibody |
|
abx025754-400l |
Abbexa |
400 µl |
EUR 518.75 |
Protein CASC4 (CASC4) Antibody |
|
abx025754-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
|
Protein CASC4 (CASC4) Antibody |
|
abx025754-80l |
Abbexa |
80 µl |
EUR 281.25 |
|
|
 (CMV) (pLenti-GIII-CMV)) CASR Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV699511 |
ABM |
1.0 ug DNA |
EUR 1626 |
 (UbC) (pLenti-GIII-UbC)) CASR Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV699515 |
ABM |
1.0 ug DNA |
EUR 1626 |
 (CMV) (pLenti-GIII-CMV)) CAST Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV680095 |
ABM |
1.0 ug DNA |
EUR 1626 |
 (UbC) (pLenti-GIII-UbC)) CAST Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV680099 |
ABM |
1.0 ug DNA |
EUR 1626 |
CAST Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV680125 |
ABM |
1.0 ug DNA |
EUR 1626 |
CAST Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV680129 |
ABM |
1.0 ug DNA |
EUR 1626 |
CAST Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV680149 |
ABM |
1.0 ug DNA |
EUR 818.4 |
CAST Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV680153 |
ABM |
1.0 ug DNA |
EUR 818.4 |
 (CMV) (pLenti-GIII-CMV)) CASK Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV676645 |
ABM |
1.0 ug DNA |
EUR 1626 |
 (UbC) (pLenti-GIII-UbC)) CASK Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV676649 |
ABM |
1.0 ug DNA |
EUR 1626 |
 (CMV) (pLenti-GIII-CMV)) CASP8 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV655159 |
ABM |
1.0 ug DNA |
EUR 818.4 |
 (UbC) (pLenti-GIII-UbC)) CASP8 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV655163 |
ABM |
1.0 ug DNA |
EUR 818.4 |
 (CMV) (pLenti-GIII-CMV)) CASP7 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV656287 |
ABM |
1.0 ug DNA |
EUR 616.8 |
 (UbC) (pLenti-GIII-UbC)) CASP7 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV656291 |
ABM |
1.0 ug DNA |
EUR 616.8 |
 (CMV) (pLenti-GIII-CMV)) CASP4 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV640789 |
ABM |
1.0 ug DNA |
EUR 818.4 |
 (UbC) (pLenti-GIII-UbC)) CASP4 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV640793 |
ABM |
1.0 ug DNA |
EUR 818.4 |
 (CMV) (pLenti-GIII-CMV)) CASQ1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV667651 |
ABM |
1.0 ug DNA |
EUR 818.4 |
 (UbC) (pLenti-GIII-UbC)) CASQ1 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV667655 |
ABM |
1.0 ug DNA |
EUR 818.4 |
 (CMV) (pLenti-GIII-CMV)) CASP9 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV668899 |
ABM |
1.0 ug DNA |
EUR 818.4 |
 (UbC) (pLenti-GIII-UbC)) CASP9 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV668903 |
ABM |
1.0 ug DNA |
EUR 818.4 |
 (CMV) (pLenti-GIII-CMV)) CASP3 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV699943 |
ABM |
1.0 ug DNA |
EUR 616.8 |
 (UbC) (pLenti-GIII-UbC)) CASP3 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV699947 |
ABM |
1.0 ug DNA |
EUR 616.8 |
 (CMV) (pLenti-GIII-CMV)) CASP1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV678997 |
ABM |
1.0 ug DNA |
EUR 818.4 |
 (UbC) (pLenti-GIII-UbC)) CASP1 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV679001 |
ABM |
1.0 ug DNA |
EUR 818.4 |
 (CMV) (pLenti-GIII-CMV)) CASP2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV677605 |
ABM |
1.0 ug DNA |
EUR 818.4 |
 (UbC) (pLenti-GIII-UbC)) CASP2 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV677609 |
ABM |
1.0 ug DNA |
EUR 818.4 |
 (CMV) (pLenti-GIII-CMV)) CASQ2 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV667315 |
ABM |
1.0 ug DNA |
EUR 818.4 |
 (UbC) (pLenti-GIII-UbC)) CASQ2 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV667319 |
ABM |
1.0 ug DNA |
EUR 818.4 |
 (EF1a) (pLenti-GIII-EF1a)) CASR Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV699516 |
ABM |
1.0 ug DNA |
EUR 1626 |
 (CMV) (pLenti-GIII-CMV)) CASP12 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV678865 |
ABM |
1.0 ug DNA |
EUR 818.4 |
 (UbC) (pLenti-GIII-UbC)) CASP12 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV678869 |
ABM |
1.0 ug DNA |
EUR 818.4 |
 (EF1a) (pLenti-GIII-EF1a)) CAST Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV680100 |
ABM |
1.0 ug DNA |
EUR 1626 |
CAST Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV680130 |
ABM |
1.0 ug DNA |
EUR 1626 |
CAST Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV680154 |
ABM |
1.0 ug DNA |
EUR 818.4 |
 (EF1a) (pLenti-GIII-EF1a)) CASK Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV676650 |
ABM |
1.0 ug DNA |
EUR 1626 |
 (EF1a) (pLenti-GIII-EF1a)) CASP8 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV655164 |
ABM |
1.0 ug DNA |
EUR 818.4 |
 (EF1a) (pLenti-GIII-EF1a)) CASP7 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV656292 |
ABM |
1.0 ug DNA |
EUR 616.8 |
 (EF1a) (pLenti-GIII-EF1a)) CASP4 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV640794 |
ABM |
1.0 ug DNA |
EUR 818.4 |
 (EF1a) (pLenti-GIII-EF1a)) CASQ1 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV667656 |
ABM |
1.0 ug DNA |
EUR 818.4 |
 (CMV) (pLenti-GIII-CMV)) CASKIN1 Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV) |
|
LV668263 |
ABM |
1.0 ug DNA |
EUR 2727.6 |
 (UbC) (pLenti-GIII-UbC)) CASKIN1 Lentiviral Vector (Rat) (UbC) (pLenti-GIII-UbC) |
|
LV668267 |
ABM |
1.0 ug DNA |
EUR 2727.6 |
 (EF1a) (pLenti-GIII-EF1a)) CASP9 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV668904 |
ABM |
1.0 ug DNA |
EUR 818.4 |
 (EF1a) (pLenti-GIII-EF1a)) CASP3 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV699948 |
ABM |
1.0 ug DNA |
EUR 616.8 |
 (EF1a) (pLenti-GIII-EF1a)) CASP1 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV679002 |
ABM |
1.0 ug DNA |
EUR 818.4 |
 (EF1a) (pLenti-GIII-EF1a)) CASP2 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV677610 |
ABM |
1.0 ug DNA |
EUR 818.4 |
 (EF1a) (pLenti-GIII-EF1a)) CASQ2 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV667320 |
ABM |
1.0 ug DNA |
EUR 818.4 |
 (CMV) (pLenti-GIII-CMV)) CASKP1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|
LV758441 |
ABM |
1.0 ug DNA |
Ask for price |
 (UbC) (pLenti-GIII-UbC)) CASKP1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|
LV758445 |
ABM |
1.0 ug DNA |
Ask for price |
 (CMV) (pLenti-GIII-CMV)) CASP12 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|
LV758459 |
ABM |
1.0 ug DNA |
Ask for price |
 (UbC) (pLenti-GIII-UbC)) CASP12 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|
LV758463 |
ABM |
1.0 ug DNA |
Ask for price |
 (CMV) (pLenti-GIII-CMV)) CASP16 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|
LV758465 |
ABM |
1.0 ug DNA |
Ask for price |
 (UbC) (pLenti-GIII-UbC)) CASP16 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|
LV758469 |
ABM |
1.0 ug DNA |
Ask for price |
 (EF1a) (pLenti-GIII-EF1a)) CASP12 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV678870 |
ABM |
1.0 ug DNA |
EUR 818.4 |
 (EF1a) (pLenti-GIII-EF1a)) CASKIN1 Lentiviral Vector (Rat) (EF1a) (pLenti-GIII-EF1a) |
|
LV668268 |
ABM |
1.0 ug DNA |
EUR 2727.6 |
 (CMV) (pLenti-GIII-CMV)) CASP1P3 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|
LV758447 |
ABM |
1.0 ug DNA |
Ask for price |
 (UbC) (pLenti-GIII-UbC)) CASP1P3 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|
LV758451 |
ABM |
1.0 ug DNA |
Ask for price |
 (CMV) (pLenti-GIII-CMV)) CASP3P1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|
LV758453 |
ABM |
1.0 ug DNA |
Ask for price |
 (UbC) (pLenti-GIII-UbC)) CASP3P1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|
LV758457 |
ABM |
1.0 ug DNA |
Ask for price |
 (CMV) (pLenti-GIII-CMV)) CASP1P1 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|
LV720497 |
ABM |
1.0 ug DNA |
Ask for price |
 (UbC) (pLenti-GIII-UbC)) CASP1P1 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|
LV720501 |
ABM |
1.0 ug DNA |
Ask for price |
 (CMV) (pLenti-GIII-CMV)) CASP1P2 Lentiviral Vector (Human) (CMV) (pLenti-GIII-CMV) |
|
LV720503 |
ABM |
1.0 ug DNA |
Ask for price |
 (UbC) (pLenti-GIII-UbC)) CASP1P2 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC) |
|
LV720507 |
ABM |
1.0 ug DNA |
Ask for price |
 (EF1a) (pLenti-GIII-EF1a)) CASKP1 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|
LV758446 |
ABM |
1.0 ug DNA |
Ask for price |
 (EF1a) (pLenti-GIII-EF1a)) CASP12 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|
LV758464 |
ABM |
1.0 ug DNA |
Ask for price |
 (EF1a) (pLenti-GIII-EF1a)) CASP16 Lentiviral Vector (Human) (EF1a) (pLenti-GIII-EF1a) |
|
LV758470 |
ABM |
1.0 ug DNA |
Ask for price |
) Luciferase-mCherry Lentiviral Vector (CMV) |
|
LV010138 |
ABM |
1.0 μg |
EUR 230 |
Afterhyperpolarizations of PLTS cells had a shorter time to peak than these of LA cells. PLTS cells fired each Na(+)-dependent, persistent depolarization spikes and Ca(2+)-dependent, low-threshold spikes along with quick spikes. Low-threshold spikes in PLTS cells had been induced solely from hyperpolarized potentials. Both persistent depolarizations and low-threshold spikes may be evoked by synaptic activation. PLTS cells had been histochemically recognized as NADPH diaphorase-positive cells. As all NADPH diaphorase-positive cells in the identical tissue had been immunoreactive for nitric oxide (NO) synthase, PLTS cells had been thought of to launch NO. PLTS cells had the largest axonal fields.
